Methods and compositions to treat glycosaminoglycan-associated molecular interactions

Abstract

Therapeutic compounds and methods for inhibiting a glycosaminoglycan (GAG)-associated molecular interaction in a subject, whatever its clinical setting, are described

1 . A method of treating a condition associated with a glycosaminoglycan-associated molecular interaction in a subject, comprising administering to a subject a therapeutically effective amount of a therapeutic compound for modulating said glycosaminoglycan-associated molecular interaction, said therapeutic compound having the formula:  
       Q[—Y − X + ] n    
     wherein Y −  is an anionic group at physiological pH; Q is a carrier molecule; X +  is a cationic group; and n is an integer selected such that the biodistribution of said therapeutic compound for an intended target site is not prevented while maintaining activity of the therapeutic compound, or a pharmaceutically acceptable salt or ester thereof, such that said glycosaminoglycan-associated molecular interaction is modulated and said condition is treated.